Pharma-Bio Serv, Inc.
PBSV · OTC
7/31/2025 | 4/30/2025 | 1/31/2025 | 10/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.05 | -0.28 | 0.42 | -0.58 |
| FCF Yield | 1,691.19% | -2.90% | -3.12% | -0.59% |
| EV / EBITDA | 25,684.01 | -228.50 | -160.08 | -62.69 |
| Quality | ||||
| ROIC | -2.62% | -0.75% | 0.00% | 1.15% |
| Gross Margin | 29.25% | 33.87% | 31.08% | 31.14% |
| Cash Conversion Ratio | -1.16 | -3.16 | -50.31 | 4.87 |
| Growth | ||||
| Revenue 3-Year CAGR | 378.21% | -19.11% | -19.81% | -21.15% |
| Free Cash Flow Growth | 77,433.84% | 28.79% | -446.49% | 88.31% |
| Safety | ||||
| Net Debt / EBITDA | 25,776.77 | 52.80 | 172.92 | 61.08 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.04 | 47.13 | 47.38 | 33.69 |